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Intermittent programmed compression of the chronically ischemic limb is associated with arteriogenesis. However,
progenitor cell elements contributing to this neovascularization are typically diminished in number and function in the
elderly dysvascular patient, particularly in the presence of diabetes, renal insufficiency, and cardiac disease. Granulocyte-
colony stimulation factor (G-CSF) dramatically boosts the circulating progenitor cell count. G-CSF was administered in
2 patients being treated for ischemic wounds with an intermittent programmed pneumatic compression device (PPCD).
Both had comorbidities associated with diminished circulating progenitor cell counts. Remarkable clinical, hemody-
namic, and angiographic improvement was observed. Further study of this synergistic strategy is warranted. (J Vasc Surg
2010;52:199-204.)Thediminishednumber and functionof circulating repar-
ative progenitor cells impairs neovascularization in the elderly
dysvascular patient.1-3 Diabetes, heart failure, and renal insuf-
ficiency compound this deficit.4-6 Furthermore, the rate of
presentation of these cells to the ischemic tissue is diminished
by the impaired arterial inflow. As such, autogenous angio-
genesis is particularly disadvantaged in the populationmost in
need: the patient with chronic limb ischemia.
The ArtAssist Device (ACI Medical, Inc, San Marcos,
Calif) is an intermittent programmable pneumatic com-
pression device (PPCD) used to increase arterial blood flow
in patients with chronic limb ischemia.7-10 Sequential ve-
nous emptying under calf, ankle, and foot pneumatic com-
pression cuffs increases the arteriovenous gradient locally,
which lowers the resistance across the capillary network and
increases blood flow into the ischemic tissue. Additionally,
the rapid cuff inflation is believed to cause the endothelium
to release nitric oxide, a powerful vasodilator11,12 and
stimulator of arteriogenesis (the formation and widening of
medium-sized blood vessels).13 The association of PPCD
use with arteriogenesis has been inferred from angiogra-
phy,14 sustained improved arterial hemodynamics, and in-
creased skin perfusion.15 However, PPCD use is associated
with variable outcomes, particularly in elderly patients with
diabetes, renal failure, and/or congestive heart failure. We
believe this, in part, may be attributed to the reduced
number and function of circulating reparative progenitor
cells in these populations.
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We report on the clinical course of 2 patients treated with
granulocyte-colony stimulation factor (G-CSF) and an inter-
mittent programmable pneumatic compression device (PPCD).
G-CSF is a cytokine growth factor that dramatically boosts the
circulating number of reparative progenitor (stem) cells16-18
needed for neovascularization. G-CSF also induces endothelial
cells to proliferate and migrate, and stimulates repair of mechan-
ically wounded endothelial monolayers.19,20 G-CSF-assisted
neovascularization strategies have been reported clinically.21-23
We believe G-CSF will potentiate the arteriogenesis observed
with PPCD use by providing the needed boost in the depleted
circulating stem cell pool reported in these patients.
METHODS
Programmed pneumatic compression device. The 2
patients were treated at their homes with the ArtAssist
Device (ACI Medical, Inc, San Marcos, Calif) in the seated
position for 1 hour at a time 3 times daily until the wounds
healed.
G-CSF administration. Filgrastim (Amgen Inc,
Thousand Oaks, Calif) was administered subcutaneously in
the arm at a dose of 10mcg/kg once every 3 days for a total
of 10 doses. This differs from the Food and Drug Admin-
istration approved dose for stem cell mobilization in oncol-
ogy applications: 10 mcg/kg daily, followed by plasma-
pheresis on day 5. The reason is that our protocol does not
require plasmapheresis. We expect the concentration of
reparative progenitor cells to increase dramatically follow-
ing G-CSF dosing, followed by homing of a significant
number of these cells to the ischemic tissues elaborating the
appropriate signaling proteins (eg, SDF-1). The white
blood cell count rose from 7  2  103 cells/mL at the
time of injection to 27 3 103 cells/mL on the next day,
and fell to 16  5  103 cells/mL by 48 hours. For this
reason, we dosed the G-CSF on every third day. By giving
10 doses, the effect was extended throughout the first
month of PPCD use. Our 72-hour dosing interval may also
reduce the rare incidence of myocardial infarction and of
splenic rupture reported with G-CSF.
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July 2010200 Eton and YuFig 1. Patient 1 serial images of transmetatarsal wound. A, One month after angioplasty of femoral-peroneal graft
angioplasty occluded and outflow embolized. B, Six weeks after panel A, granulation tissue beginning to form after
wound completely opened. C, Wound healed after 5 months using the ArtAssist Device and 10 granulocyte-colony
stimulation factor (G-CSF) injections in the first month.Fig 2. Patient 1 pulse volume recordings. A, Ankle brachial index (ABI) was 0 (September 25, 2009), and there was
no pulsatility at the ankle level prior to enrollment. B, ABI 0.43 on April 8, 2009, and pulsatility returned at the left
ankle. C, ABI  0.64 on June 3, 2009.
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Volume 52, Number 1 Eton and Yu 201Clinical summaries. Patient 1 is an active 56-year-old
white male who developed necrosis of a previously healed
transmetatarsal amputation (TMA). His medical history
includes bilateral carotid endarterectomy, coronary artery re-
vascularization, and femoral-peroneal bypass with TMA for
forefoot gangrene. He is human immunosufficiency virus
(HIV) positive and is on antiretroviral therapy. His viral
counts were undetectable. During surveillance of the graft,
progressive stenosis of the conduit led to catheter angioplasty
Fig 3. Patient 1 angiography. Panels A to D were obtained on
initial referral. Panels E toH were obtained at 6-month follow-up.
Note the increased collateral vessels at all levels from above the
knee (E vs A), below the knee (F vs B), the calf (G vs C), and the
ankle (H vs D).6 months after surgery. This was complicated by distal graftocclusion and outflow embolization.His healed TMAwound
completely dehisced. In lieu of below knee amputation, he
consented to the combined strategy of G-CSF and use of the
PPCD, with approval from his HIV physician. Enrollment
startedOctober 17, 2008. The openTMAwound (Fig 1)was
managed with Silvercel (Johnson and Johnson, Warren, NJ)
and eventually healed. The transcutaneous oxygen tension
(TcPO2) on the foot dorsum rose from 3 mm Hg pre-
enrollment to 24 mmHg (April 8, 2009). The ankle brachial
index (ABI) rose from 0 (September 25, 2008) to 0.43 (April
8, 2009) to 0.64 (June 3, 2009). Ankle pulsatility was absent
on enrollment, but was observed onApril 8, 2009 and June 3,
2009 pulse volume recordings (Fig 2). Fig 3 shows the re-
markable neovascularization by angiography.
Patient 2 is a 44-year-old morbidly obese female, insulin-
dependent diabetic with a history of coronary revascular-
ization, renal insufficiency, and congestive heart failure who
was referred after her second failed left leg bypass. She had
an exposed Achilles’ tendon, a dorsal ankle ulcer, and
ischemic rest pain. Superficial femoral, popliteal, and tibial
artery occlusive disease reduced her ABI to 0.4. Previous
iliac stents had been placed for ipsilateral external iliac
artery stenoses. She was enrolled October 7, 2008. An
equine pericardium (Pegassus, Irvine, Calif) was applied for
5 weeks, then removed. AlloDerm (LifeCell, Branchburg,
NJ) was applied after a 1-month hiatus and removed 4
weeks later. Silvercel was applied when there was no bio-
logic dressing. Fig 4 shows the healing progression of the
large ulcer over her exposed Achilles’ tendon. The pre-
enrollment TcPO2 measured from the skin overlying the
medial calcaneous and on the foot dorsum was 23 mm Hg
(September 18, 2008) and 1 mm Hg (October 7, 2008),
respectively. These rose to 46 and 35 mm Hg (September
22, 2009). No pulsatility was recorded on her pre-enrollment
pulse volume recording at themetatarsal level (September 18,
2008), at which time her ABI was 0.43. Pulsatility was seen at
this level on August 17, 2009, at which time her ABI was
0.64. This was confirmed on the November 18, 2009 study
(Fig 5). Photoplethysmography documents absence of pulsa-
tility in the toes until November 2009, when pusatility was
recorded for the first time in the first toe (Fig 6). Fig 7 shows
Fig 4. Patient 2 exposed Achilles’ tendon. A,On presentation.
B, Five months later. C, One year after presentation.the neovascularization by angiography.
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Investigators have attempted to promote neovascular-
ization by delivering large numbers of progenitor cells
directly into ischemic tissue in a single session, either by
Fig 6. Patient 2 photoplethysmography documents ab
Fig 5. Patient 2 pulse volume recordings (PVR). A, Pr
transmetatarsal level (September 18, 2008), at which tim
January 8, 2009. C, ABI  0.58 on April 8, 2009. D,
August 17, 2009, at which time her ABI was 0.64, confir
November 18, 2009 PVR shown.pusatility was recorded for the first time in the first toe.multiple intramuscular injections or by arterial emboliza-
tion. Our approach avoids the associated costly and invasive
hospital-based bone marrow harvest, ex vivo cell process-
ing, and cell reinjection required in these neovasculariza-
of pulsatility in the toes until November 2009, when
enrollment, no pulsatility was recorded on PVR at the
ankle brachial index (ABI) was 0.43. B, ABI 0.53 on
rn of pulsatility was seen at the transmetatarsal level on
n the November 18, 2009 PVR shown, confirmed in thesenceior to
e her
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Volume 52, Number 1 Eton and Yu 203Fig 7. Patient 2 angiography. Panels A to E were obtained on initial referral: panel A is femoral; panel B is
above-the-knee popliteal; panel C is below-the-knee popliteal; panelD is the calf; and panel E is the ankle. Panels F to
L were obtained at 1-year follow-up.
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problems of nonuniform progenitor cell distribution after
direct injection into the ischemic calf musculature, along
with the limited survival of these cells. While single-session
intra-arterial injection has the potential to provide a more
uniform progenitor cell distribution, significant “pass-
through” results in cell sequestration in other organs.
Healing of a dehiscedTMAwound, or of an ankle wound
with an exposed Achilles’ tendon, would be challenging even
in the setting of good arterial perfusion.That healing occurred
in the setting of severe ischemia suggests efficacy. The healing
was correlated with hemodynamic and angiographic evidence
of neovascularization. This occurred despite severe comor-
bidities in both patients: coronary artery disease in both and
renal insufficiency, diabetes, and congestive heart failure in
patient 2. Nevertheless, this report is limited by the small
number of subjects (n  2) and the lack of control groups.
Moreover, the preoperative angiograms were provided by the
referring institutions, using different equipment and contrast
injection protocols than those used for the final angiograms.
Lastly, unlike the immediate revascularization benefit pro-
vided by catheter or surgical interventions, this strategy took
manymonths to achieve wound healing.Whether healing can
be further accelerated by alternate G-CSF dosimetry or by
increasing the frequency of daily PPCD sessions, or both,
remains to be seen. Potent new stem cell mobilization strate-
gies are being developed.
A prospective randomized study comparing use of the
PPCD alone with PPCD plus G-CSF will be needed to
confirm synergy.
REFERENCES
1. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg
D, Ramaswami P, et al. Aging, progenitor cell exhaustion, and athero-
sclerosis. Circulation 2003;108:457-63.
2. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi
AA, Finkel T. Circulating endothelial progenitor cells, vascular func-
tion, and cardiovascular risk. N Engl J Med 2003;348:593-600.
3. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired
progenitor cell activity in age-related endothelial dysfunction. J AmColl
Cardiol 2005;45:1441-8.
4. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al.
Number and migratory activity of circulating endothelial progenitor
cells inversely correlate with risk factors for coronary artery disease. Circ
Res 2001;89:E1-7.
5. Loomans CJ, de Koning EJ, Staal FJ, RookmaakerMB, VerseydenC, de
BoerHC, et al. Endothelial progenitor cell dysfunction: a novel concept
in the pathogenesis of vascular complications of type 1 diabetes. Diabe-
tes 2004;53:195-9.
6. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz
GR, et al. Human endothelial progenitor cells from type II diabetics7. Louridas G, Saadia R, Spelay J, Abdoh A, Weighell W, Arneja AS, et al.
The ArtAssist Device in chronic lower limb ischemia. A pilot study. Int
Angiol 2002;21:28-35.
8. van Bemmelen PS, Gitlitz DB, Faruqi RM, Weiss-Olmanni J, Brunetti
VA, Giron F, Ricotta JJ. Limb salvage using high-pressure intermittent
compression arterial assist device in cases unsuitable for surgical revas-
cularization. Arch Surg 2001;136:1280-5; discussion 1286.
9. Montori VM, Kavros SJ, Walsh EE, Rooke TW. Intermittent compres-
sion pump for nonhealing wounds in patients with limb ischemia. The
Mayo Clinic experience (1998-2000). Int Angiol 2002;21:360-6.
10. Kavros SJ, Delis KT, Turner NS, Voll AE, Liedl DA, Gloviczki P, Rooke
TW. Improving limb salvage in critical ischemia with intermittent
pneumatic compression: a controlled study with 18-month follow-up. J
Vasc Surg 2008;47:543-9.
11. Liu K, Chen LE, Seaber AV, Urbaniak JR. Influences of inflation rate
and duration on vasodilatory effect by intermittent pneumatic compres-
sion in distant skeletal muscle. J Orthop Res 1999;17:415-20.
12. Guzman RJ, Abe K, Zarins CK. Flow-induced arterial enlargement is
inhibited by suppression of nitric oxide synthase activity in vivo. Surgery
1997;122:273-9; discussion 279-80.
13. Unthank JL, Fath SW, Burkhart HM, Miller SC, Dalsing MC. Wall
remodeling during luminal expansion of mesenteric arterial collaterals
in the rat. Circ Res 1996;79:1015-23.
14. van Bemmelen P, Char D, Giron F, Ricotta JJ. Angiographic improve-
ment after rapid intermittent compression treatment (ArtAssist) for
small vessel obstruction. Ann Vasc Surg 2003;17:224-8.
15. Eze AR, Comerota AJ, Cisek PL,Holland BS, Kerr RP, Veeramasuneni R,
Comerota AJ Jr. Intermittent calf and foot compression increases lower
extremity blood flow. Am J Surg 1996;172:130-4; discussion 135.
16. Bolwell B, Goormastic M, Dannley R, Andresen S, Overmoyer B,
Mendez Z, et al. G-CSF post-autologous progenitor cell transplanta-
tion: a randomized study of 5, 10, and 16 micrograms/kg/day. Bone
Marrow Transplant 1997;19:215-9.
17. Haas R, Murea S. The role of granulocyte colony-stimulating factor in
mobilization and transplantation of peripheral blood progenitor and
stem cells. Cytokines Mol Ther 1995;1:249-70.
18. Gazitt Y. Comparison between granulocyte colony-stimulating factor and
granulocyte-macrophage colony-stimulating factor in the mobilization of
peripheral blood stem cells. Curr Opin Hematol 2002;9:190-8.
19. Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O,
et al. In vitro and in vivo activation of endothelial cells by colony-
stimulating factors. J Clin Invest 1991;87:986-95.
20. Bussolino F, Colotta F, Bocchietto E, Guglielmetti A, Mantovani A.
Recent developments in the cell biology of granulocyte-macrophage
colony-stimulating factor and granulocyte colony-stimulating factor:
activities on endothelial cells. Int J Clin Lab Res 1993;23:8-12.
21. Kudo FA,Nishibe T, NishibeM, Yasuda K. Autologous transplantation of
peripheral blood endothelial progenitor cells (CD34) for therapeutic
angiogenesis in patients with critical limb ischemia. Int Angiol 2003;22:
344-8.
22. Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, et al.
Clinical study of therapeutic angiogenesis by autologous peripheral
blood stem cell (PBSC) transplantation in 92 patients with critically
ischemic limbs. J Artif Organs 2006;9:226-33.
23. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous
transplantation of granulocyte colony-stimulating factor-mobilized pe-
ripheral blood mononuclear cells improves critical limb ischemia in
diabetes. Diabetes Care 2005;28:2155-60.exhibit impaired proliferation, adhesion, and incorporation into vascu-
lar structures. Circulation 2002;106:2781-6. Submitted Nov 12, 2009; accepted Dec 16, 2009.
AVAILABILITY OF JOURNAL BACK ISSUES
As a service to our subscribers, copies of back issues of Journal of Vascular Surgery for the preceding 5 years are
maintained and are available for purchase from Mosby until inventory is depleted. Please write to Elsevier Inc.,
Subscription Customer Service, 11830 Westline Industrial Drive, St. Louis, MO, or call 800-654-2452 (U.S. and
Canada); 314-453-7041 (outside U.S. and Canada) for information on availability of particular issues and prices.
